Sort
82,697 grants matching “vaccine development”
Molecular Biology of Oncogenic Papillomaviruses
$996,660Peter M Howley · Harvard Medical School · R35 · FY2022 · CA
Molecular mechanisms of antibody-mediated immunotherapies
$996,658Jeffrey Victor Ravetch · Rockefeller University · R35 · FY2022 · CA
Innovative Optical System for Hemagglutination Assays
$996,634Kathy L Rowlen · Indevr, Inc. · R44 · FY2016 · AI
Scanning B. pseudomallei proteome for vaccine antigens
$996,535Philip Louis Felgner · University Of California-Irvine · U01 · FY2007 · AI
Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine
$996,500Kenneth C Bagley · Orlance, Inc. · R44 · FY2023 · AI
The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship
$996,487Paula J Bates · University Of Louisville · U01 · FY2017 · HL
NONHUMAN PRIMATE CORE HUMORAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT (COVID-19)
$996,432Rob Caudle · Duke University · N01 · FY2020 · AI
Optimization of Protein Therapeutics Formulations
$996,395Lawrence J Delucas · Soluble Therapeutics, Inc. · R42 · FY2012 · GM
Novel G protein-based RSV vaccine
$996,326Shengqiang Li · Sciogen, Llc · R44 · FY2024 · AI
Marketing Strategic Plan and Distribution Logistics for Sanaria PfSPZ Vaccine against Malaria.
$996,292Stephen Lev Hoffman · Sanaria, Inc. · SB1 · FY2017 · AI
Defining T cell epitopes in Dengue virus infection
$996,155Ramila Philip · Immunotope, Inc. · R44 · FY2012 · AI
Origin and maturation of protective memory B cell responses against pathogenic viruses in natural infections and upon vaccination.
$995,831Mattia Bonsignori · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Structure-guided neutralizing antibodies developed using EpiVolve technology
$995,774Xiaofeng Li · Abbratech, Inc. · R44 · FY2024 · AI
Development of a Group B Streptococcus bioconjugate vaccine
$995,682Christian Harding · Vaxnewmo, Llc · R44 · FY2024 · AI
Development of a Group B Streptococcus bioconjugate vaccine
$995,682Christian Harding · Vaxnewmo, Llc · R44 · FY2025 · AI
In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV
$995,652Richard A Cone · Mucommune, Llc · R44 · FY2021 · AI
Development of World's First Fully Human Broad Spectrum Anti-Snake Venom
$995,570Jacob Glanville · Centivax Inc · R44 · FY2024 · AI
Development of World's First Fully Human Broad Spectrum Anti-Snake Venom
$995,570Jacob Glanville · Centivax Inc · R44 · FY2023 · AI
Novel Therapy for Pulmonary Anthrax
$995,532Keith Wycoff · Planet Biotechnology, Inc. · R44 · FY2012 · AI
Novel Therapeutic Strategies Targeting Re-emerging Alphaviruses
$995,510Daniel N Streblow · University Of Alabama At Birmingham · U19 · FY2015 · AI
Evaluation and Production of a Multivalent Adenoviral Plague Vaccine
$995,493Eric Rothe · Norwell, Inc. · R44 · FY2012 · AI
Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites
$995,482Sumana Chakravarty · Sanaria, Inc. · U44 · FY2024 · AI
A Vaccine for Lymphatic Filariasis, LFGuardâ¢
$995,460Darrick Albert Carter · Pai Life Sciences, Inc. · R44 · FY2024 · AI
NLM's Personal Health Record and Consumer Service R&D
$995,428Clement McDonald · National Library Of Medicine · ZIA · FY2012 · LM
Recombinant antigen diagnostics for filoviruses
$995,262Kelly R Pitts · Corgenix Medical Corporation · R44 · FY2014 · AI